Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACTS<br />
Jan Öhrström<br />
Chief Executive Officer<br />
Arnoud Dijkstra<br />
Chief Business Officer<br />
L Diepgrond<br />
ADDRESS<br />
Zernikedreef 9<br />
2333 CK, Leiden<br />
The Netherlands<br />
TELEPHONE<br />
+31 888 669 665<br />
FAX<br />
+31 715 181 340<br />
EMAIL<br />
j.ohrstrom@profibrix.com<br />
a.dijkstra@profibrix.com<br />
l.diepgrond@profibrix.com<br />
YEAR FOUNDED<br />
2005<br />
ProFibrix BV<br />
www.profibrix.com<br />
FINANCIAL SUMMARY<br />
Completed B round and added EUR 15Mill in May 2011.<br />
COMPANY PROFILE<br />
ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the<br />
hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and<br />
tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field<br />
of hemostasis. Fibrocaps, the proposed name of the company’s lead biologic, is being studied to help stop<br />
bleeding during surgery and after trauma injury. A dry powder based on a mixture of fibrinogen and thrombin,<br />
Fibrocaps is a ready-to-use preparation designed to be stable at room temperature and applied in different<br />
formats, including sprays and bandages. Fibrocaps is currently enrolling patients into a final pivotal Phase 3<br />
study and aiming at submitting a BLA/MAA in mid-2013.<br />
MANAGEMENT<br />
Jan Öhrström, CEO<br />
Jaap Koopman. CSO<br />
Arnoud Dijkstra, CBO<br />
Martijn Meijer, VP Finance<br />
Eliane Schutte, CDO<br />
Paul Frohna, CMO<br />
Linda Zuckerman, VP Preclinical<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language